Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations

Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations

Abstract Background Based on the CAPItello-291 phase III trial results, capivasertib in combination with fulvestrant has been approved for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer harboring one or more PIK3CA, AKT1, and/or PTEN...

Full description

Saved in:
Bibliographic Details
Main Authors: Moumita Chaki, Mona Benrashid, Subir Puri, Smruthy Sivakumar, Ethan S. Sokol, Josefa M. Briceno, Neil Vasan
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Breast Cancer Research
Subjects:
AKT inhibitor
Capivasertib
Targeted therapy
Breast cancer
Next-generation sequencing
Circulating tumor DNA
Online Access:https://doi.org/10.1186/s13058-025-02055-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items